Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6182271

CCCCC1(C(=O)OCC)CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.43
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 1/20 0.36
SMYD3 Q9H7B4 1/20 0.36
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
FUCA1 P04066 1/20 0.35
NPY1R P25929 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2025300 0.90 OPRM1 (0.47) OPRM1ALDH1A1L3MBTL1KMT2AMEN1
Trifluoroacetic Acid SCHEMBL1309429 0.86 OPRM1 (0.47) OPRM1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL13269452 0.81 OPRM1 (0.49) OPRM1L3MBTL1KMT2AMEN1MAPT
SCHEMBL10285599 0.80 OPRM1 (0.46) OPRM1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL744367 0.77 MAPK1 (0.45) OPRM1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL378407 0.77 OPRM1 (0.46) OPRM1KMT2AMEN1MAPTPOLB
Trifluoroacetic Acid SCHEMBL6134916 0.76 FUCA1 (0.35) OPRM1KMT2AMEN1PKMCYP2D6
SCHEMBL13282000 0.76 MAPK1 (0.44) OPRM1ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL8071102 0.76 CYP4F2 (0.45) ALDH1A1L3MBTL1KMT2AMEN1MAPT
SCHEMBL11345271 0.76 CYP4F2 (0.49) ALDH1A1L3MBTL1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187614-A4 SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2005-06-22 EP disclosed
US-20020137664-A1 Substituted piperidines as melanocortin-4 receptor agonists MERCK & CO., INC. 2002-09-26 US disclosed
EP-1187614-A1 SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS Merck & Co., Inc. (US) 2002-03-20 EP disclosed
US-6350760-B1 OBESITY, DIABETES, SEXUAL DYSFUNCTION; MERCK & CO., INC. 2002-02-26 US disclosed
WO-2000074679-A1 SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO., INC. (US) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137664-A1 Substituted piperidines as melanocortin-4 receptor agonists MC4R, MC5R, MC3R OPRM1 86/4885ALDH1A1 3013/4885L3MBTL1 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.